<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0106257506
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PAQUIX 2.5MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APIXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        224.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma Saudi " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Pharmacotherapeutic group:</strong></p><p><strong>Paquix<sup>&reg;</sup></strong> contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood dots from forming by blocking Factor Xa which is an important component of blood clotting.</p><p><strong>Paquix<sup>&reg;</sup></strong> is used in adults:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations. After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. This can cause the legs to swell, with or without pain. If a blood clot travels from your leg to your lungs, it can block blood flow causing breathlessness, with or without chest pain. This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood dots may break off and travel to the brain and lead to a stock or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and require immediate medical attention.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat blood dots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and\or lugs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take Paquix<sup>&reg;</sup></strong> <strong>if:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to apixaban or any of the other ingredients of this medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are bleeding excessively</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a disease in an organ of the body that increase the risk of serious bleeding (such as an active or a recent ulcer at your stomach or bowel. recent bleeding in your brain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are taking medicines to prevent blood clotting (e.g. warfarin. rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment or while having a venous or arterial line and you get heparin through this line to keep it open.</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;<strong>Take special care with Paquix<sup>&reg;</sup></strong></p><p><strong>Before taking Paquix<sup>&reg;</sup>, tell your doctor about all of your medical conditions, including if you have any the following:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased risk of bleeding, such as.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders, including conditions resulting in reduced platelet activity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure, not controlled by medical treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are older than 75 years</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you weigh 60 kg or less</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe kidney disease or if you are on dialysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A liver problem or a history of liver problems <strong>Paquix<sup>&reg;</sup></strong> will be used with caution in patients with signs of altered liver function.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a prosthetic heart valve</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood dot from your lungs is planned</p><p>If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while, If you are not sure whether a procedure may cause bleeding ask your doctor.</p><p><strong>Children and adolescents</strong></p><p><strong>Paquix<sup>&reg;</sup></strong> is not recommended in children and adolescents under 18 years of age.</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor, pharmacist or nurse it you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may increase the effects of <strong>Paquix<sup>&reg; </sup></strong>and some may decrease its effects. Your doctor will decide, if you should be treated with <strong>Paquix<sup>&reg;</sup></strong> when taking these medicines and how closely you should be monitored.</p><p>The following medicines may increase the effects of <strong>Paquix<sup>&reg; </sup></strong>and increase the chance for unwanted bleeding:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines for fungal infections (e.g. ketoconazole, etc.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antiviral medicines for HIV\AIDS (e.g., Ritonavir);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-inflammatory or pain medicines (e.g. aspirin or naproxen). Especially, if you are older than 75 years and are taking aspirin. You may have an increased change of bleeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for high blood pressure or heart problems (e.g.. diltiazem)</p><p>The following medicines may reduce the ability of <strong>Paquix<sup>&reg;</sup></strong> to help prevent blood clots from forming:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to prevent epilepsy or seizures (e.g. phenytoin. etc.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (a herbal supplement used for depression)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat tuberculosis or other infections (e.g. rifampicin)</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast-feeding </strong></p><p><strong>Pregnancy </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant ae planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>The effects of <strong>Paquix<sup>&reg;</sup></strong> on pregnancy and the unborn child are not known. You should not take <strong>Paquix<sup>&reg; </sup></strong>if you are pregnant. Contact your doctor immediately if you become pregnant while taking <strong>Paquix<sup>&reg;</sup></strong>.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>It is not known if <strong>Paquix<sup>&reg;</sup></strong> passes into human breast mills. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you to either stop breast-feeding or to stop/not start taking <strong>Paquix<sup>&reg;</sup></strong>.<strong> </strong></p><p><strong>e.&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p><strong>Paquix<sup>&reg;</sup></strong> has not been shown to impair your ability to drive or use machine.</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients:</strong></p><p><strong>Paquix<sup>&reg; </sup></strong>contains lactose (a type of sugar). It you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Route of Administration:</strong> Oral.</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p><strong>Dosage</strong></p><p>For <strong>Paquix&reg; 2.5mg</strong> ,the score line is only to facilitate breaking for ease of swallowing and <strong>not</strong> to divide into equal doses .</p><p><u>To prevent blood clots from forming after hip or knee replacement operations.</u></p><p>The recommended dose is one tablet of <strong>Paquix<sup>&reg; </sup></strong>2.5 mg twice a day.</p><p>For example, one in the morning and one in the evening. Try to take the tablets at the same times every day to have the best treatment effect.</p><p>You should take the first tablet 12 to 24 hours after your operation.</p><p>If you have had a major hip operation you will usually take the tablets for 32 to38 days</p><p>If you have had a major knee operation you will usually take the tablets for 10 to 14 days</p><p><u>To prevent a blood clot from forming in the heart in patients with an irregular heartbeat and at least one additional risk factor.</u></p><p>The recommended dose is one tablet of <strong>Paquix<sup>&reg;</sup></strong> 5 mg twice a day.</p><p>The recommended dose is one tablet of <strong>Paquix<sup>&reg;</sup></strong> 2.5 mg twice a day if,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severely reduced kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two or more of the following apply to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole\L) or greater)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are 80 years old or older</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your weight is 60 kg or lower.</p><p>The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Try to take the tablets at the same times every day to have the best treatment effect.</p><p>Swallow the tablet with a drink of water. <strong>Paquix<sup>&reg; </sup></strong>can be taken with or without food.</p><p>Your doctor will decide how long you must continue treatment.</p><p>&nbsp;</p><p><u>To treat blood clots in the veins of your legs and blood clots in the blood vessels your lungs.</u></p><p>The recommended dose is two tablets of <strong>Paquix<sup>&reg;</sup></strong> 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening.</p><p>After 7 days, the recommended dose is one tablet of <strong>Paquix<sup>&reg;</sup></strong> 5 mg twice a day, for example, one in the morning and one in the evening. Try to take the tablets at the same times every day to have the best treatment effect.</p><p>&nbsp;</p><p><u>For preventing blood clots from re-occurring following completion of 6 months of treatment</u></p><p>The recommended dose is one tablet of <strong>Paquix<sup>&reg; </sup></strong>2.5 mg twice a day for example one in the morning and one in the evening. Try to take the tablets at the same times every day to have the best treatment effect.</p><p>Your doctor will decide how long you must continue treatment.</p><p>&nbsp;</p><p><strong>Your doctor might change your anticoagulant treatment as follows:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from </em><strong>Paquix<em><sup>&reg;</sup></em></strong> <em>to anticoagulant medicines</em>:</p><p>Stop taking <strong>Paquix<sup>&reg;</sup></strong>. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from anticoagulant medicines to </em><strong>Paquix<em><sup>&reg;</sup></em></strong><em>:</em></p><p>Stop taking the anticoagulant medicines. Start treatment with <strong>Paquix<sup>&reg;</sup></strong> at the time you would have had the next dose of anticoagulant medicine, then continue as normal.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from treatment with anticoagulant containing Vitamin K antagonist (e.g. warfarin) to </em><strong>Paquix<em><sup>&reg;</sup></em></strong><em>: </em></p><p>Stop taking the medicine containing a vitamin-K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking <strong>Paquix<sup>&reg;</sup></strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Changing from </em><strong>Paquix<sup>&reg;</sup></strong> <em>to anticoagulant treatment containing Vitamin K antagonist (e.g. warfarin): </em></p><p>If your doctor tells you that you have to start taking the medicine containing a Vitamin- K antagonist, continue to take <strong>Paquix<sup>&reg; </sup></strong>for at least 2 days after your first dose of the medicine containing a Vitamin-K antagonist. Your doctor needs to do blood measurements and instruct you when to stop taking <strong>Paquix<sup>&reg;</sup></strong>.<strong> </strong></p><p><strong>a.&nbsp;&nbsp;&nbsp; </strong><strong>If you take more Paquix<sup>&reg;</sup></strong> <strong>than you should</strong></p><p>Tell your doctor immediately if you have taken more than the prescribed dose of <strong>Paquix<sup>&reg;</sup></strong>. Take the medicine pack with you even if there are no tablets left.</p><p>If you take more <strong>Paquix<sup>&reg;</sup></strong> than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery or blood transfusions may be required.</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take </strong><strong>Paquix<sup>&reg;</sup></strong></p><p>Take the tablet as soon as you remember and Take the next tablet of <strong>Paquix<sup>&reg; </sup></strong>at the usual time then Continue as normal. If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you stop taking Paquix<sup>&reg;</sup></strong></p><p>Do not stop taking <strong>Paquix<sup>&reg; </sup></strong>without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.</p><p>If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. <strong>Paquix<sup>&reg;</sup></strong>can be given for two different medical conditions. The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below. For both conditions, the most common general side effect of <strong>Paquix<sup>&reg;</sup></strong> is bleeding which may be potentially life threatening and require immediate medical attention.</p><p><u>The following side effects are known if you take </u><strong><u>Paquix<sup>&reg; </sup></u></strong><u>to prevent blood clots from forming after hip or knee replacement operations.</u></p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>- Anaemia which may cause tiredness or paleness</p><p>- Bleeding including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the urine (that stains the urine pink or red)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising and swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal bleeding</p><p>- Nausea (feeling sick)</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>- Reduced number of platelets in your blood (which can affect clotting)</p><p>- Bleeding including:</p><ul><li>bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion)</li><li>bleeding in your stomach, bowel or blood in the stools</li><li>blood found in the urine</li><li>bleeding from your nose</li></ul><p>- Low blood pressure which may make you feel faint or have a quickened heartbeat</p><p>- Blood tests may show:</p><ul><li>abnormal liver function</li><li>an increase in some liver enzymes</li><li>an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.</li></ul><p><strong>Rare side effects (may affect up to 1 in 1000 people)</strong></p><p>- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. <strong>Contact your doctor immediately </strong>if you experience any of these symptoms.</p><p>- Bleeding:</p><ul><li>into a muscle</li><li>in your eyes</li><li>from your gums and blood in your spit when coughing</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from your rectum</p><p><u>The following side effects are known if you take <strong>Paquix<sup>&reg;</sup></strong><sup> </sup>to prevent a blood clot from forming in the heart in patients with irregular heart beat and at least one additional risk factor.</u></p><p><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>Bleeding including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your stomach, bowel or dark/black blood in the stools</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood found in the urine on laboratory testing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From your nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From your gums</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising and swelling</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>Bleeding including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your brain or in your spinal column</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your mouth or blood in your spit when coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Into your abdomen, into the rectum or from the vagina</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bright/red blood in the stools</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site</p><p>Allergic reactions (hypersensitivity) which may cause:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, mouth, tongue and\or throat and difficulty breathing.</p><p>Contact your doctor immediately if you experience any of these symptoms.</p><p><strong>Rare side effects (may affect up to 1 in 1000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in your lungs or your throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding into the space behind your abdominal cavity</p><p><u>The following side effects are known if you take <strong>Paquix<sup>&reg;</sup></strong><sup> </sup>to treat or prevent re-occurring of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.</u></p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>Bleeding including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From your nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From your gums</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in the urine (that stains the urine pink or red)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising and swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your stomach, your bowel into the rectum</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>Bleeding including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your eyes and bruise of the eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your mouth or blood in your spit when coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dark/black blood in the stools</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Into the uterus or from the vagina</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests showing blood in the stools or in the urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising and swelling of a wound or injection site</p><p><strong>Rare side effects (may affect up to 1 in 1000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal pendency to spontaneous bleeding, loss of red blood cells due to bleeding</p><p>Bleeding including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In your abdomen, lungs or in the reembrace surrounding the heart.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Paquix<sup>&reg; </sup></strong>after the expiry date which is stated on the blister and carton after &ldquo;Exp.&rdquo; The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient of <strong>Paquix<sup>&reg;</sup></strong><strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>Paquix<sup>&reg;</sup></strong> <strong>2.5mg F.C. Tablets </strong>Each film coated tablet contains Apixaban 2.5 mg.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Paquix<sup>&reg;</sup></strong> <strong>5mg F.C. Tablets: </strong>Each film coated tablet contains Apixaban 5 mg.</p><p>The other ingredients are</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Paquix<sup>&reg; </sup></strong><strong>2.5mg F.C. Tablets</strong>: Lactose, Microcrystalline Cellulose, Croscarmellose Sodium, Sodium Lauryl Sulphate, Magnesium Stearate, Opadry White OYL &amp; Yellow Iron Oxide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Paquix<sup>&reg;</sup></strong> <strong>5mg F.C. Tablets</strong>: Lactose, Microcrystalline Cellulose, Croscarmellose Sodium, Sodium Lauryl Sulphate, Magnesium Stearate, Opadry White OYL &amp; Red Iron Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -	Paquix® 2.5 mg F.C. Tablets are packed of 60 F.C. Tablets (10 F.C. Tablets / Blister, 6 Blisters/ Pack) and 30 F.C. Tablets (10 F.C. Tablets / Blister, 3 Blisters/ Pack) in a carton box.
-	Paquix® 5 mg F.C. Tablets are packed of 60 F.C. Tablets (10 F.C. Tablets / Blister, 6 Blisters/ Pack) in a carton box.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>&nbsp;United Pharmaceutical Mfg. Co. Ltd. for MS Pharma-Saudi.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oct-19
SPM190342

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>المجموعة</strong><strong>&nbsp;</strong><strong>العلاجية</strong><strong>: </strong></p><p dir="RTL">يحتوي <strong>باكويكس</strong> &nbsp;على المادة الفعالة أبيكسابان وينتمي إلى مجموعة من الأدوية التي تسمى مضادات التخثر. يساعد هذا الدواء على منع تشكل نقاط الدم عن طريق منع العامل العاشر أ والذي يعد مكونًا مهمًا لتخثر الدم.</p><p dir="RTL">يستخدم <strong>باكويكس</strong> في البالغين:</p><p dir="RTL">- لمنع تجلط الدم (تجلط الأوردة العميقة [DVT]) من التكوين بعد استبدال الورك أو الركبة. بعد عملية في الورك أو الركبة ، قد تكون في خطر متزايد من تخثر الدم في أوردة الساق. هذا يمكن أن يسبب بتضخم الأرجل ، مع أو بدون ألم. إذا تحركت الجلطة الدموية من ساقك إلى رئتيك ، فقد تعيق تدفق الدم ، مما يسبب ضيق في التنفس ، مع أو بدون ألم في الصدر. يمكن أن تكون هذه الحالة (الانسداد الرئوي) مهددًا للحياة ويتطلب عناية طبية فورية.</p><p dir="RTL">- لمنع تشكل جلطة دموية في القلب لدى المرضى الذين يعانون من ضربات القلب غير المنتظمة (الرجفان الأذيني) بوجود عامل خطر إضافي واحد على الأقل. قد تتفكك نقاط الدم وتنتقل إلى الدماغ وتؤدي إلى سكتة دماغية أو التحرك إلى أعضاء أخرى وتمنع تدفق الدم الطبيعي إلى هذا العضو (المعروف أيضًا باسم الانسداد الشرياني). قد تكون السكتة الدماغية مهددة للحياة وتتطلب عناية طبية فورية.</p><p dir="RTL">- لعلاج نقاط الدم في عروق ساقيك (تجلط الأوردة العميقة) وفي الأوعية الدموية في رئتيك (انسداد رئوي)، ومنع حدوث الجلطات الدموية في الأوعية الدموية في ساقيك و \ أو رئتيك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ.لا تأخذ </strong><strong>باكويكس</strong><strong> </strong><strong>إذا:</strong></p><p dir="RTL">- كان لديك حساسية من أبيكسابان أو لأي من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">- كنت تنزف بشكل مفرط</p><p dir="RTL">- كان لديك مرض في أحد أعضاء الجسم يزيد من خطر حدوث نزيف خطير (مثل قرحة نشطة أو حديثة في المعدة أو الأمعاء. نزيف حديث في الدماغ)</p><p dir="RTL">- كان لديك مرض في الكبد مما يؤدي إلى زيادة خطر النزيف (اعتلال تجلط الدم الكبدي)</p><p dir="RTL">- كنت تتناول أدوية لمنع تجلط الدم (على سبيل المثال الوارفارين، أو ريفاروكابان أو دابيجاتران أو الهيبارين)، إلا عند تغيير علاجك المضاد للتجلط أو أثناء وجود خط وريدي أو شرياني، وتستعمل الهيبارين لهذا الخط لإبقائه مفتوحًا.</p><p dir="RTL"><strong>ب.قبل أخذ </strong><strong>باكويكس</strong><strong> </strong><strong>، أخبر طبيبك عن جميع حالاتك الطبية، بما في ذلك إذا كان لديك أي مما يلي:</strong></p><p dir="RTL">- زيادة خطر النزيف، مثل:</p><p dir="RTL">&bull; اضطرابات النزيف، بما في ذلك الظروف التي تؤدي إلى انخفاض نشاط الصفائح الدموية</p><p dir="RTL">&bull; ارتفاع ضغط الدم، غير مسيطر علية باستعمال الأدوية</p><p dir="RTL">&bull; كنت أكبر من 75 عامًا</p><p dir="RTL">&bull; تزن 60 كلغم أو أقل</p><p dir="RTL">- مرض شديد في الكلى أو إذا كنت تحت غسيل للكلى</p><p dir="RTL">- مشكلة في الكبد أو تاريخ من مشاكل الكبد سيتم استخدام <strong>باكويكس</strong> <strong> </strong>بحذر في المرضى الذين يعانون من أعراض تغير في وظائف الكبد.</p><p dir="RTL">- كان لديك صمام قلب اصطناعي</p><p dir="RTL">- إذا قرر طبيبك أن ضغط دمك غير مستقر أو أن هناك علاج آخر أو إجراء جراحي لإزالة نقطة الدم من رئتيك</p><p dir="RTL">إذا كنت بحاجة إلى إجراء جراحة أو إجراء قد يسبب النزيف، قد يطلب منك الطبيب التوقف مؤقتًا عن تناول هذا الدواء لفترة قصيرة، إذا لم تكن متأكدًا مما إذا كان الإجراء قد يسبب نزيفًا استشر طبيبك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح باستخدام <strong>باكويكس</strong> في الأطفال والمراهقين دون سن 18 سنة من العمر.</p><p dir="RTL"><strong>ج</strong><strong>. </strong><strong>التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرض الأدوية التي تتناولها، أو قد تناولتها مؤخرًا أو إذا كنت تتناول أي أدوية أخرى. قد تزيد بعض الأدوية من تأثيرات <strong>باكويكس</strong> <strong> </strong>وقد يقلل بعضها من آثارها. سوف يقرر طبيبك، وجوب اكمال العلاج مع <strong>باكويكس</strong> عند تناول هذه الأدوية ومدى حاجتك للمراقبة.</p><p dir="RTL">قد تزيد الأدوية التالية من تأثيرات <strong>باكويكس</strong> وتزيد من فرص حدوث نزيف غير مرغوب به:</p><p dir="RTL">- بعض الأدوية للالتهابات الفطرية (مثل كيتوكونازول، إلخ.)</p><p dir="RTL">- بعض الأدوية المضادة للفيروسات لعلاج فيروس نقص المناعة البشرية / الإيدز (مثل ريتونافير)؛</p><p dir="RTL">- أدوية أخرى والتي تستخدم للحد من تخثر الدم (على سبيل المثال، إينوكسبارين، إلخ.)</p><p dir="RTL">- الأدوية المضادة للالتهابات أو الألم (مثل الأسبرين أو النابروكسين). خاصة، إذا كنت أكبر من 75 سنة وتتناول الأسبرين. قد يكون لديك تغير متزايد في النزيف.</p><p dir="RTL">- أدوية علاج ارتفاع ضغط الدم أو مشاكل في القلب (على سبيل المثال ديلتيازم).</p><p dir="RTL">الأدوية التالية قد تقلل من قدرة <strong>باكويكس</strong> للمساعدة في منع تشكل جلطات الدم:</p><p dir="RTL">- أدوية لمنع حدوث الصرع أو النوبات (مثل فينيتوين، الخ.)</p><p dir="RTL">- نبتة سانت جون (وهو مكمل عشبي يستخدم للاكتئاب)</p><p dir="RTL">- أدوية لعلاج السل أو غيره من الأمراض (مثل ريفامبيسين).</p><p dir="RTL"><strong>د. القيادة واستخدام الآلات</strong></p><p dir="RTL">لم يثبت أن <strong>باكويكس</strong> يضعف من قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>ه.معلومات مهمة حول بعض المكونات:</strong></p><p dir="RTL">يحتوي <strong>باكويكس</strong> على لاكتوز (نوع من السكريات). إذا أخبرك طبيبك أن لديك عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL"><strong>و.الاستخدام خلال فترة الحمل والرضاعة:</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة رضاعة طبيعية، تعتقدين بأنك قد تكوني حاملًا، تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي أو الممرض قبل تناول هذا الدواء.</p><p dir="RTL">آثار <strong>باكويكس</strong> على الحمل والطفل الذي لم يولد بعد غير معروفة. يجب عدم تناول <strong>باكويكس</strong> إذا كنت حاملاً. اتصل بالطبيب على الفور إذا أصبحت حاملاً أثناء تناول <strong>باكويكس</strong> <strong>.</strong></p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">ليس من المعروف ما إذا كان <strong>باكويكس</strong> يمر في حليب الثدي البشري. استشيري طبيبك أو الصيدلي أو الممرض قبل تناول هذا الدواء أثناء الرضاعة الطبيعية. سوف ينصحونك إما بإيقاف الرضاعة الطبيعية أو التوقف / عدم البدء بتناول <strong>باكويكس</strong> <strong>.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>طريقة الإعطاء: عن طريق الفم.</strong></p><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلي. استشر طبيبك أو الصيدلي أو الممرض إذا كنت غير متأكد.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>بالنسبة لباكويكس ٢,٥ ملغم ، فإن الخط على القرص هو فقط لتسهيل كسر القرص لسهولة البلع ولا يستخدم &nbsp;لتقسيم القرص إلى جرعات متساوية.</strong></p><p dir="RTL"><u>لمنع تشكل جلطة دموية في القلب في المرضى الذين يعانون من عدم انتظام ضربات القلب وعامل خطر إضافي واحد على الأقل.</u></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من <strong>باكويكس</strong> 5 ملغم مرتين في اليوم.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من <strong>باكويكس</strong> 2.5 ملغم مرتين في اليوم إذا،</p><p dir="RTL">- قلت وظائف الكلى بشدة</p><p dir="RTL">- ينطبق عليك اثنان أو أكثر مما يلي:</p><p dir="RTL">- تشير نتائج فحص الدم إلى ضعف في وظائف الكلى (مستوى كرياتينين المصل هو 1.5 ملغم / ديسيلتر (133 ميكرومول / لتر) أو أعلى)</p><p dir="RTL">- تبلغ من العمر 80 عامًا أو أكثر</p><p dir="RTL">- وزنك 60 كلغم أو أقل.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد مرتين في اليوم، على سبيل المثال، واحد في الصباح وواحد في المساء. حاول أن تأخذ الأقراص في نفس الأوقات كل يوم للحصول على أفضل تأثير علاجي.</p><p dir="RTL">ابلع القرص بشرب الماء. يمكن تناول <strong>باكويكس</strong> مع الطعام أو بدونه.</p><p dir="RTL">سيحدد الطبيب المدة التي يجب عليك مواصلة العلاج فيها.</p><p dir="RTL"><u>لعلاج نقاط الدم في عروق ساقيك وجلطات الدم في الأوعية الدموية في رئتيك.</u></p><p dir="RTL">الجرعة الموصى بها هي قرصين من <strong>باكويكس</strong> 5 ملغم مرتين في اليوم خلال الأيام السبعة الأولى، على سبيل المثال، اثنان في الصباح واثنان في المساء.</p><p dir="RTL">بعد 7 أيام، تكون الجرعة الموصى بها هي قرص واحد من <strong>باكويكس</strong> 5 ملغم مرتين في اليوم، على سبيل المثال، واحد في الصباح وواحد في المساء. حاول أن تأخذ الأقراص في نفس الأوقات كل يوم للحصول على أفضل تأثير علاجي.</p><p dir="RTL"><u>لمنع تجلط الدم من حدوثه بعد الانتهاء من 6 أشهر من العلاج</u></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من <strong>باكويكس</strong> 2.5 ملغم مرتين في اليوم على سبيل المثال واحد في الصباح وواحد في المساء. حاول أن تأخذ الأقراص في نفس الأوقات كل يوم للحصول على أفضل تأثير علاجي.</p><p dir="RTL">سيحدد الطبيب المدة التي يجب عليك مواصلة العلاج فيها.</p><p dir="RTL"><strong><em>قد يقوم طبيبك بتغيير علاجك المضاد للتخثر كما يلي:</em></strong></p><p dir="RTL">- التغيير من <strong>باكويكس</strong> إلى الأدوية المضادة للتخثر الاخرى:</p><p dir="RTL">&nbsp;التوقف عن تناول <strong>باكويكس</strong> <strong>. </strong>ابدأ العلاج مع الأدوية المضادة للتخثر (على سبيل المثال الهيبارين) في الوقت الذي كنت ستأخذ القرص التالي.</p><p dir="RTL">- التغيير من الأدوية المضادة للتخثر الأخرى إلى <strong>باكويكس</strong> :</p><p dir="RTL">&nbsp;التوقف عن تناول الأدوية المضادة للتخثر. ابدأ العلاج باستخدام <strong>باكويكس</strong> في الوقت الذي كنت ستأخذ فيه الجرعة التالية من الدواء المضاد للتخثر، ثم استمر بشكل طبيعي.</p><p dir="RTL">&bull; اﻟﺗﻐﯾﯾر ﻣن اﻟﻌﻼج ﺑﻣﺿﺎدات اﻟﺗﺧﺛر اﻟﺗﻲ ﺗﺣﺗوي ﻋﻟﯽ ﻣﺿﺎد ﻓﯾﺗﺎﻣﯾن ك (ﻋﻟﯽ ﺳﺑﯾل اﻟﻣﺛﺎل، وارﻓﺎرﯾن) إﻟﯽ - <strong>باكويكس</strong> يجب إﯾﻘﺎف ﺗﻧﺎول اﻟدواء اﻟذي ﯾﺣﺗوي ﻋﻟﯽ ﻣﺿﺎد ﻓﯾﺗﺎﻣﯾن ك. يحتاج طبيبك إلى إجراء قياسات للدم وإرشادك عند بدء استخدام <strong>باكويكس</strong> .</p><p dir="RTL">&bull; اﻟﺗﻐﯾﯾر ﻣن <strong>باكويكس</strong> <strong> </strong>إﻟﯽ ﻋﻼج ﻣﺿﺎد ﻟﻟﺗﺧﺛر ﯾﺣﺗوي ﻋﻟﯽ ﻣﺿﺎدات فيتامين ك (ﻋﻟﯽ ﺳﺑﯾل اﻟﻣﺛﺎل وارﻓﺎرﯾن):</p><p dir="RTL">&nbsp;إذا أﺧﺑرك اﻟطﺑﯾب أﻧﮫ ﯾﺟب ﻋﻟﯾك أن ﺗﺑدأ ﻓﻲ أﺧذ اﻟدواء اﻟذي ﯾﺣﺗوي ﻋﻟﯽ ﻣﺿﺎد ﻓﯾﺗﺎﻣﯾن ك، ﻓﺎﺳﺗﻣر ﻓﻲ أﺧذ <strong>باكويكس</strong> <strong> </strong>ﻟﻣدة يومين ﻋﻟﯽ اﻷﻗل. بعد أيام من تناول الجرعة الأولى من الدواء التي تحتوي على مضادات فيتامين ك. يحتاج طبيبك إلى إجراء قياسات للدم وإرشادك عند التوقف عن تناول <strong>باكويكس</strong> .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. إذا تناولت باكويكس</strong><strong> </strong><strong> أكثر مما يجب</strong></p><p dir="RTL">أخبر طبيبك على الفور إذا كنت قد أخذت أكثر من الجرعة الموصوفة من <strong>باكويكس</strong> . خذ معك علبة الدواء حتى إذا لم تكن هناك أقراص. إذا كنت تأخذ <strong>باكويكس</strong> أكثر من الموصى به، فقد يكون لديك خطر متزايد للنزيف. في حالة حدوث نزيف، قد تكون هناك حاجة لعملية جراحية أو عمليات نقل دم.</p><p dir="RTL"><strong>ب. إذا نسيت تناول باكويكس</strong><strong> </strong><strong> </strong></p><p dir="RTL">خذ القرص بمجرد تذكره و خذ القرص التالي من <strong>باكويكس</strong> في الوقت المعتاد في ذلك الوقت, استمر بشكل طبيعي. إذا لم تكن متأكدًا مما يجب فعله أو فاتتك أكثر من جرعة، فاطلب من طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL"><strong>ج. اذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong> <strong>باكويكس</strong> <strong>&nbsp;</strong></p><p dir="RTL">لا تتوقف عن تناول <strong>باكويكس</strong> <strong> </strong>دون التحدث إلى طبيبك أولاً، لأن خطر الإصابة بتجلط دموي قد يكون أعلى إذا توقفت عن العلاج مبكراً.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، استشر طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها في الجميع. قد تختلف الآثار الجانبية المعروفة ومعدل تكرار حدوثها لكل من هذه الحالات الطبية ويتم سردها بشكل منفصل أدناه. لكلتا الحالتين ،&nbsp; التأثير الجانبي العام الأكثر شيوعًا لـ <strong>باكويكس</strong>هو النزيف والذي قد يكون خطرًا على الحياة ويتطلب عناية طبية فورية.</p><p dir="RTL"><u>الآثار الجانبية التالية معروفة إذا كنت تأخذ</u><u> </u><strong><u>باكويكس</u></strong><u> </u><u>لمنع تشكل جلطات الدم بعد عمليات استبدال الورك أو الركبة</u><u>.</u></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على 1 من كل 10 أشخاص</strong><strong>)</strong></p><p dir="RTL">- فقر الدم الذي قد يسبب التعب أو شحوب</p><p dir="RTL">- نزيف يشمل:</p><p dir="RTL">&bull; الدم في البول (الذي يلوث البول الوردي أو الأحمر)</p><p dir="RTL">&bull; كدمات وتورم</p><p dir="RTL">&bull; نزيف مهبلي</p><p dir="RTL">- الغثيان (الشعور بالغثيان)</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (قد تؤثر على 1 من كل 100 شخص</strong><strong>)</strong></p><p dir="RTL">- انخفاض عدد الصفائح الدموية في الدم (مما قد يؤثر على تخثر الدم)</p><p dir="RTL">- نزيف يشمل:</p><p dir="RTL">&bull; النزيف الذي يحدث بعد العملية بما في ذلك الكدمات والورم ، أو الدم أو السائل المتسرب من الجرح / الشق الجراحي (إفراز الجرح)</p><p dir="RTL">نزيف في معدتك أو أمعائك أو دمك في البراز</p><p dir="RTL">&bull; الدم الموجود في البول</p><p dir="RTL">&bull; نزيف من أنفك</p><p dir="RTL">- انخفاض ضغط الدم الذي قد يجعلك تشعر بالإغماء أو تسارع ضربات القلب</p><p dir="RTL">- اختبارات الدم قد تظهر:</p><p dir="RTL">&bull; وظيفة الكبد غير طبيعية</p><p dir="RTL">&bull; زيادة في بعض إنزيمات الكبد</p><p dir="RTL">&bull; زيادة في البيليروبين ، وهو منتج تكسير خلايا الدم الحمراء ، والتي يمكن أن تسبب اصفرار الجلد والعينين.</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على 1 من كل 1000 شخص</strong><strong>)</strong></p><p dir="RTL">- الحساسية (فرط الحساسية) التي قد تسبب: تورم في الوجه والشفة والفم واللسان و/أو الحلق وصعوبة في التنفس. اتصل بطبيبك على الفور إذا كنت تعاني من أي من هذه الأعراض.</p><p dir="RTL">- نزيف:</p><p dir="RTL">&bull; في العضلات</p><p dir="RTL">&bull;في عينيك</p><p dir="RTL">&bull; من اللثة والدم في البصاق عند السعال</p><p dir="RTL">&bull; من المستقيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تُعرف التأثيرات الجانبية التالية إذا كنت تتناول<strong> </strong></u><strong><u>باكويكس</u></strong><strong><u> </u></strong><u>لمنع تشكل جلطة دموية في القلب في المرضى الذين يعانون من ضربات قلب غير منتظمة وعامل خطر إضافي واحد على الأقل.</u></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على 1 من كل 10 أشخاص)</strong></p><p dir="RTL">نزيف ويتضمن:</p><p dir="RTL">- عينيك</p><p dir="RTL">- معدتك أو أمعائك أو دم داكن / أسود في البراز</p><p dir="RTL">- وجود دم في البول في الفحوص المخبرية</p><p dir="RTL">- أنفك</p><p dir="RTL">- لثتك</p><p dir="RTL">- كدمات وتورم</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على 1 من كل 100 شخص)</strong></p><p dir="RTL">نزيف ويتضمن:</p><p dir="RTL">- دماغك أو العمود الفقري</p><p dir="RTL">- الفم أو ظهور دم في البصاق عند السعال</p><p dir="RTL">- البطن، في المستقيم أو من المهبل</p><p dir="RTL">- دم ظاهر / أحمر في البراز</p><p dir="RTL">- نزيف يحدث بعد أي عملية بما في ذلك الكدمات والورم، أو الدم أو السائل المتسرب من الجرح الجراحي / الشق (إفرازت الجروح) أو موقع الحقن</p><p dir="RTL">الحساسية (فرط الحساسية) والتي قد تسبب:</p><p dir="RTL">- تورم في الوجه والشفتين والفم واللسان و \ أو الحلق وصعوبة في التنفس.</p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت تعاني من أي من هذه الأعراض.</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على 1 من كل 1000 شخص)</strong></p><p dir="RTL">- نزيف في رئتيك أو حلقك</p><p dir="RTL">- نزيف في المكان خلف تجويف البطن الخاص بك</p><p dir="RTL">تُعرف الآثار الجانبية التالية إذا كنت تتناول <strong>باكويكس</strong> لعلاج أو منع حدوث الجلطات الدموية في عروق ساقيك وجلطات الدم في الأوعية الدموية في رئتيك.</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على 1 من كل 10 أشخاص)</strong></p><p dir="RTL">نزيف ويتضمن:</p><p dir="RTL">- أنفك</p><p dir="RTL">- لثتك</p><p dir="RTL">- الدم في البول (الذي يلون البول إلى وردي أو أحمر)</p><p dir="RTL">- كدمات وتورم</p><p dir="RTL">- معدتك، أمعائك إلى المستقيم</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على 1 من كل 100 شخص)</strong></p><p dir="RTL">نزيف ويتضمن:</p><p dir="RTL">- عينيك وكدمة العيون</p><p dir="RTL">- الفم أو ظهور دم في البصاق عند السعال</p><p dir="RTL">- دم داكن / أسود في البراز</p><p dir="RTL">- الرحم أو من المهبل</p><p dir="RTL">- فحوص تظهر الدم في البراز أو في البول</p><p dir="RTL">- كدمات وتورم في الجرح أو موقع الحقن</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على 1 من كل 1000 شخص)</strong></p><p dir="RTL">- توقف غير طبيعي للنزيف العفوي، وفقدان خلايا الدم الحمراء بسبب النزيف</p><p dir="RTL">نزيف ويتضمن:</p><p dir="RTL">- دماغك</p><p dir="RTL">- بطنك أو رئتيك أو في محيط القلب.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحفظ الدواء في درجة حرارة أعلى من 30<sup>о</sup> م.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل <strong>باكويكس</strong> <strong> </strong>بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة Exp. يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لا يجب أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة: أبيكسابان</p><p dir="RTL">&nbsp;<strong>باكويكس</strong> <strong> </strong>2.5<strong> </strong><strong>ملغم</strong> <strong>أقراص مغلفة:</strong> كل قرص مغلف&nbsp;يحتوي على أبيكسابان 2.5 ملغم.</p><p dir="RTL"><strong>باكويكس</strong> <strong> </strong>5<strong> </strong><strong>ملغم</strong> <strong>أقراص مغلفة</strong><strong>:</strong> كل قرص مغلف&nbsp;يحتوي على أبيكسابان 5 ملغم.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>باكويكس</strong> <strong> </strong>2.5<strong> </strong><strong>ملغم</strong> <strong>أقراص مغلفة: </strong>لاكتوز، سيليلوز دقيق التبلور، كارميلوز الصوديوم المتشابك، لوريل سلفات الصوديوم، إستيرات المغنيسيوم، اوبادراي أبيض واكسيد الحديد الاصفر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>باكويكس</strong> 5<strong> </strong><strong>ملغم</strong> <strong>أقراص مغلفة: </strong>لاكتوز، سيليلوز دقيق التبلور، كارميلوز الصوديوم المتشابك، لوريل سلفات الصوديوم، إستيرات المغنيسيوم، اوبادراي أبيض واكسيد الحديد الاحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اكويكس 2.5 ملغم</strong> <strong>أقراص مغلفة</strong><strong>:</strong> معبأة في عبوة مكونة من 60 قرص مغلف (10أقراص مغلفة / الشريط، 6 أشرطة في البكيت)، و أيضا معبأة في عبوة مكونة من 30 قرص مغلف (10أقراص مغلفة / الشريط، 3 أشرطة في البكيت), و ثم معبأة في علب كرتونية.</p><p dir="RTL"><strong>باكويكس 5</strong><strong> </strong><strong>ملغم</strong> <strong>أقراص مغلفة</strong><strong>:</strong> معبأة في عبوة مكونة من 60 قرص مغلف (10أقراص مغلفة / الشريط، 6 أشرطة في البكيت)، ثم معبأة في علب كرتونية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:&nbsp; </strong><strong>&nbsp;</strong></p><p dir="RTL">المتحدة للصناعات الدوائية <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Oct-19
SPM190342

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paquix® 2.5mg Film Coated Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Material Name	Function	Amount (mg)/one tablet
Apixaban	Active material	2.5*
Lactose	Diluent	51.43
Microcrystalline cellulose	Diluent	40.57
Crosscarmellose Sodium	Disintegrant	4.0
Sodium Lauryl Sulphate 	Anionic surfactant 	1.0
Magnesium stearate	Lubricant	0.50
Total weight before coating 	100
Opadry White OY-L (28900)	Film Coating material 	2.793
Yellow Iron Oxide 	Coloring agent 	0.207
Total weight after coating	103

*Actual quantity depends on the potency and water content of the API. 
For a full list of excipients, see section 6.1 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
Paquix® 2.5mg F.C. Tablets: Yellow round, biconvex, scored tablets embossed with "N73" from one side and plain on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses .

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.</p><p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age <strong>&ge;</strong> 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class <strong>&ge;</strong> II).</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for hemodynamically unstable PE patients).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Prevention of VTE (VTEp): elective hip or knee replacement surgery</em></p><p>The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.</p><p>Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window.</p><p><em>In patients undergoing hip replacement surgery</em></p><p>The recommended duration of treatment is 32 to 38 days.</p><p><em>In patients undergoing knee replacement surgery</em></p><p>The recommended duration of treatment is 10 to 14 days.</p><p><em>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).</em></p><p>The recommended dose of apixaban is 5 mg taken orally twice daily.</p><p><u>Dose reduction</u></p><p>The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age <strong>&ge;</strong> 80 years, body weight &le; 60 kg, or serum creatinine <strong>&ge;</strong> 1.5 mg/dL (133 micromole/L).</p><p>Therapy should be continued long-term.</p><p><u>Treatment of DVT treatment of PE and prevention of recurrent DVT and PE (VTEt).</u></p><p>The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, and immobilization).</p><p>The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table I below (see also section 5.1).</p><p>Table 1:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Maximum daily dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Treatment of DVT or PE</p></td><td style="vertical-align:top"><p>10 mg twice daily for the first 7 days</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>followed by 5 mg twice daily</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE</p></td><td style="vertical-align:top"><p>2.5 mg twice daily</p></td><td style="vertical-align:top"><p>5 mg</p></td></tr></tbody></table><p>The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><p><strong>Missed dose</strong></p><p>If a dose is missed, the patient should take <strong>Paquix<sup>&reg;</sup></strong> immediately and then continue with twice daily intake as before.</p><p><strong>Switching</strong></p><p>Switching treatment from parenteral anticoagulants to <strong>Paquix<sup>&reg;</sup></strong> (and vice versa) can be done at the next scheduled dose (see section 4.5). These medicinal products should not be administered simultaneously.</p><p><em>Switching from vitamin K antagonist (VKA) therapy to </em><strong>Paquix<sup>&reg;</sup></strong></p><p>When converting patients from vitamin K antagonist (VKA) therapy to <strong>Paquix<sup>&reg;</sup></strong>, warfarin or other VKA therapy should be discontinued and <strong>Paquix<sup>&reg; </sup></strong>started when the international normalised ratio (INR) is &lt;2.</p><p><em>Switching from </em><strong>Paquix<sup>&reg;</sup></strong><em> to VKA therapy</em></p><p>When converting patients from <strong>Paquix<sup>&reg;</sup></strong> to VKA therapy, administration of <strong>Paquix<sup>&reg;</sup></strong> should be continued for at least 2 days after beginning VKA therapy. After 2 days of coadministration of <strong>Paquix<sup>&reg;</sup></strong> with VKA therapy, an INR should be obtained prior to the next scheduled dose of <strong>Paquix<sup>&reg;</sup></strong>. Coadministration of <strong>Paquix<sup>&reg;</sup></strong> and VKA therapy should be continued until the INR is &lt; 2.</p><p><strong>Renal impairment</strong></p><p>In patients with mild or moderate renal impairment, the following recommendations apply:</p><p>- for the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).</p><p>- for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine <strong>&ge;</strong> 1.5 mg/dL (133 micromole/L) associated with age <strong>&ge;</strong> 80 years or body weights 60 kg, a dose reduction is necessary and described above. In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2).</p><p>In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):</p><p>- For the prevention of VTE in elective hip or knee replacement surgery (VTEp), for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;</p><p>- For the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.</p><p>In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).</p><p>Hepatic impairment</p><p><strong>Paquix<sup>&reg;</sup></strong> is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>It is not recommended in patients with severe hepatic impairment (see sections 4.4. and 5.2).</p><p>It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2). Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &gt;2 x ULN or total bilirubin 1.5 x ULN were excluded in clinical trials. Therefore <strong>Paquix<sup>&reg;</sup></strong> should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating <strong>Paquix<sup>&reg;</sup></strong>, liver function testing should be performed.</p><p>VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).</p><p>NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).</p><p><strong>Gender</strong></p><p>No dose adjustment required (see section 5.2).</p><p><strong>Elderly</strong></p><p>VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).</p><p>NVAF - No dose adjustment required, unless Criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).</p><p><strong>Patients undergoing cardioversion</strong></p><p>Apixaban can be initiated or continued in NVAF patients who may require cardioversion.</p><p>For patients not previously treated with anticoagulants, at least 5 doses of apixaban 5 mg twice daily (2.5 mg twice daily in patients who qualify for a dose reduction (see above sections Dose reduction and Renal impairment)) should be given before cardioversion to ensure adequate anticoagulation (see section 5.1).</p><p>If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment). The administration of the loading dose should be given at least 2 hours before cardioversion (see section 5.1).</p><p>Confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p><strong>Paediatric population</strong></p><p>The safety and efficacy of <strong>Paquix<sup>&reg;</sup></strong> in children and adolescents below age 18 have not been established. No data are available.</p><p><strong>Method of administration</strong></p><p>Oral use</p><p><strong>Paquix<sup>&reg;</sup></strong> should be swallowed with water, with or without food.</p><p>For patients who are unable to swallow whole tablets, <strong>Paquix<sup>&reg;</sup></strong> tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2). Alternatively, <strong>Paquix<sup>&reg;</sup></strong> tablets may be crushed and suspended in 60 mL of water or DSW and immediately delivered through a nasogastric tube (see section 5.2).</p><p>Crushed <strong>Paquix<sup>&reg;</sup></strong> tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active clinically significant bleeding.
• Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
• Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
• Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Hemorrhage risk</em></p><p>As with other anticoagulants, patients taking <strong>Paquix<sup>&reg;</sup></strong> are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of hemorrhage. Apixaban administration should be discontinued if severe hemorrhage occurs (see sections 4.8 and 4.9).</p><p>Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).</p><p><em>Interaction with other medicinal products affecting hemostasis</em></p><p>Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).</p><p>The concomitant use of apixaban with antiplatelet agents increases the risk of bleeding (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.</p><p>Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with apixaban (see section 4.5).</p><p>In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with apixaban.</p><p>In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.</p><p>In a clinical trial of high-risk post acute coronary syndrome patients, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Hemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).</p><p><em>Use of thrombolytic agents for the treatment of acute ischemic stroke</em></p><p>There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban.</p><p><em>Patients with prosthetic heart valves</em></p><p>Safety and efficacy of apixaban have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of apixaban is not recommended in this setting.</p><p><em>Surgery and invasive procedures</em></p><p>Apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable.</p><p>Apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled.</p><p>If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention. Apixaban should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate hemostasis has been established (for cardioversion see section 4.2).</p><p><em>Temporary discontinuation</em></p><p>Discontinuing anticoagulants, including apixaban, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with apixaban must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.</p><p><em>Spinal/epidural anaesthesia or puncture</em></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters must be removed at least 5 hours prior to the first dose of apixaban. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thrombo-prophylaxis.</p><p>There is no clinical experience with the use of apixaban with indwelling intrathecal or epidural catheters. In case there is such need and based on the general PK characteristics of apixaban, a time interval of 20-30 hours (i.e., 2 x half-life) between the last dose of apixaban and catheter withdrawal should elapse, and at least one dose should be omitted before catheter withdrawal. The next dose of apixaban may be given at least 5 hours after catheter removal. As with all new anticoagulant medicinal products, experience with neuraxial blockade is limited and extreme caution is therefore recommended when using apixaban in the presence of neuraxial blockade.</p><p>Hemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy.</p><p>Apixaban is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are hemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.</p><p><em>Patients with active cancer</em></p><p>Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established.</p><p><em>Patients with renal impairment </em></p><p>Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk. For the prevention of VTE in elective hip or knee replacement surgery (VTEp), the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2).</p><p>For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine <strong>&ge;</strong> 1.5 mg/dL (133 micromole/L) associated with age  80 years or body weight  60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2).</p><p>In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).</p><p><em>Elderly patients</em></p><p>Increasing age may increase hemorrhagic risk (see section 5.2).</p><p>Also, the coadministration of apixaban with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk.</p><p>Low body weight (&lt; 60 kg) may increase hemorrhagic risk (see section 5.2).</p><p><em>Patients with hepatic impairment</em></p><p>Apixaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>It is not recommended in patients with severe hepatic impairment (see section 5.2).</p><p>It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2).</p><p>Patients with elevated liver enzymes ALT/AST &gt; 2 x ULN or total bilirubin  1.5 x ULN were excluded in clinical trials. Therefore apixaban should be used cautiously in this population (see section 5.2). Prior to initiating apixaban, liver function testing should be performed.</p><p><em>Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp).</em></p><p>The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5), or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).</p><p><em>Interaction with inducers of both CYP3A4 and P-gp</em></p><p>The concomitant use of apixaban with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John&rsquo;s Wort) may lead to a -50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.</p><p>In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp the following recommendations apply (see section 4.5):</p><p>- For the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;</p><p>- For the treatment of DVT and treatment of PE, apixaban should not be used since efficacy may be compromised.</p><p><em>Hip fracture surgery</em></p><p>Apixaban has not been studied in clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety in these patients. Therefore, it is not recommended in these patients.</p><p><em>Laboratory parameters</em></p><p>Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).</p><p><em>Information about excipients</em></p><p><strong>Paquix<sup>&reg;</sup></strong> contains<strong> </strong>lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Inhibitors of CYP3A4 and P-gp</strong></p><p>Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban C<sub>max</sub>.</p><p>The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and H IV protease inhibitors (e.g., ritonavir) (see section 4.4).</p><p>Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, and quinidine) are expected to increase apixaban plasma concentration to a lesser extent. No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp. For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in C<sub>max</sub>. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and C<sub>max</sub>, respectively. Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and C<sub>max</sub> respectively.</p><p><strong>Inducers of CYP3A4 and P-g</strong></p><p>Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and C<sub>max</sub>, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John&rsquo;s Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.</p><p>Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).</p><p><strong>Anticoagulants, platelet aggregation inhibitors, SSRIs/SNRIs and NSAIDs</strong></p><p>Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).</p><p>After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed.</p><p>Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.</p><p>Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.</p><p>Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Corresponding increases in clotting tests were observed for apixaban. No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen.</p><p>Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban. <strong>Paquix<sup>&reg;</sup></strong> should be used with caution when coadministered with SSRIs/SNRIs or NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk. A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4).</p><p>Medicinal products associated with serious bleeding are not recommended concomitantly with apixaban, such as: thrombolytic agents, GP IIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone.</p><p><strong>Other concomitant therapies</strong></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or C<sub>max</sub>.</p><p><strong>Effect of apixaban on other medicinal products</strong></p><p>In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (lC5O &gt;45 &micro;M) and weak inhibitory effect on the activity of CYP2CI9 (lC50 &gt;20 &micro;M) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYPIA2, CYP2BS, and CYP3A4/5 at a concentration up to 20 &micro;M. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.</p><p>In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.</p><p><strong>Digoxin</strong></p><p>Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or C<sub>max</sub>. Therefore, apixaban does not inhibit P-gp mediated substrate transport.</p><p><strong>Naproxen</strong></p><p>Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or C<sub>max</sub>.</p><p><strong>Atenolol</strong></p><p>Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol.</p><p><strong>Activated charcoal</strong></p><p>Administration of activated charcoal reduces apixaban exposure (see section 4.9).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy.</p><p><em>Breast-feeding</em></p><p>It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio (Cmax about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.</p><p>A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.</p><p><em>Fertility</em></p><p>Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apixaban has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days, 1.7 years and 221 days respectively (see section 5.1).</p><p>Common adverse reactions were hemorrhage, contusion, epistaxis, and hematoma (see Table 2 for adverse reaction profile and frequencies by indication).</p><p>In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions. The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.</p><p>In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study. In the apixaban vs warfarin study the incidence of 18TH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18% year.</p><p>In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1). Tabulated list of adverse reactions</p><p>Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (<strong>&ge;</strong> 1/10); common (<strong>&ge;</strong> 1/100 to &lt; 1/10); uncommon (<strong>&ge;</strong> 1/1,000 to &lt; 1/100); rare (<strong>&ge;</strong> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively.</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (<strong>&ge;</strong> 1/10); common (<strong>&ge;</strong> 1/100 to &lt; 1/10); uncommon (<strong>&ge;</strong> 1/1,000 to &lt; 1/100); rare (<strong>&ge;</strong> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTE<sup>t</sup> respectively.</p><table border="1" cellspacing="0" cellpadding="0" style="width:658px"><tbody><tr><td style="vertical-align:top"><p><strong>SYSTEM ORGAN CLASS</strong></p></td><td style="vertical-align:top"><p><strong>Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp)</strong></p></td><td style="vertical-align:top"><p><strong>Prevention of stroke</strong></p><p><strong>and systemic</strong></p><p><strong>embolism in adult</strong></p><p><strong>patients with NVAF,</strong></p><p><strong>with one or more risk factors (NVAF)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Immune system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity, allergic oedema and Anaphylaxis</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Brain hemorrhage <sup>t</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Eye disorders</p></td></tr><tr><td style="vertical-align:top"><p>Eye hemorrhage (including conjunctival hemorrhage)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage, hematoma</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension (including procedural hypotension)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hemoptysis</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal hemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhoidal hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Mouth hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hematochezia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rectal hemorrhage, gingival bleeding</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retroperitoneal hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Hepatobiliary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Liver function test abnormal, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>Skin rash</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>Muscle hemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Renal and urinary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Hematuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal vaginal hemorrhage, urogenital</p><p>hemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>General disorders and administration site conditions</p></td></tr><tr><td style="vertical-align:top"><p>Application site bleeding</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Investigations</p></td></tr><tr><td style="vertical-align:top"><p>Occult blood positive</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td></tr><tr><td style="vertical-align:top"><p>Contusion</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Post procedural hemorrhage (including post procedural hematoma, wound hemorrhage, vessel puncture site hematoma and catheter site hemorrhage), wound secretion, incision site hemorrhage (including incision site hematoma), operative hemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Traumatic hemorrhage</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>* There were no occurrences of generalized pruritus in CV185057 (long term prevention of VTE)</p><p><sup>t</sup> The term &ldquo;Brain hemorrhage&rdquo; encompasses all intracranial or intraspinal hemorrhages (i.e., hemorrhagic stroke or putamen, cerebellar, intraventricular, or subdural hemorrhages).</p><p>The use of apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in post hemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>National Pharmacovigilance &amp; Drug Safety Centre (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone : 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <strong>npc.drug@sfda.gov.sa</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>-&nbsp;&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no antidote to apixaban. Overdose of apixaban may result in a higher risk of bleeding. In the event of hemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical hemostasis or the transfusion of fresh frozen plasma should be considered.</p><p>In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.</p><p>In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUG by 50% and 27%, respectively, and had no impact on Cmax. Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.</p><p>If life-threatening bleeding cannot be controlled by the above measures, administration of prothrombin complex concentrates (PCC5) or recombinant factor Vila may be considered. Reversal of apixaban pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30 minute infusion in healthy subjects. However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received apixaban. Currently there i no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.</p><p>Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.</p><p>Hemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally. Therefore, hemodialysis is unlikely to be an effective means of managing apixaban overdose.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF02</p><p><strong>Mechanism of action</strong></p><p>Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved hemostasis.</p><p><strong>Pharmacodynamic effects</strong></p><p>The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.</p><p>Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. Data from clinical trials are only available for the <em>Rotachrom<sup>&reg;</sup> Heparin chromogenic assay</em>. Anti-FXa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-FXa activity is approximately linear over a wide dose range of apixaban.</p><p>Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication. In patients taking apixaban for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels. In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong><em>Table 3: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Apix.</p><p>C<sub>max</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>Apix.</p><p>C<sub>min</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>Apix. Anti-Xa Activity Max (IU/mL)</p></td><td style="vertical-align:top"><p>Apix. Anti-Xa&nbsp; Activity Min (IU/mL)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Median [5<sup>th</sup>, 95<sup>th</sup> Percentile]</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Prevention of VTE: elective hip or knee replacement surgery</em></p></td></tr><tr><td style="vertical-align:top"><p>2.5mg twice daily</p></td><td style="vertical-align:top"><p>77 [41, 146]</p></td><td style="vertical-align:top"><p>51 [23,109]</p></td><td style="vertical-align:top"><p>1.3 [0.67, 2.4]</p></td><td style="vertical-align:top"><p>0.84 [0.37, 1.8]</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Prevention of stroke and systemic embolism: NVAF</em></p></td></tr><tr><td style="vertical-align:top"><p>2.5mg twice daily*</p></td><td style="vertical-align:top"><p>123 [69, 221]</p></td><td style="vertical-align:top"><p>79[34, 162]</p></td><td style="vertical-align:top"><p>1.8 [1.0, 3.3]</p></td><td style="vertical-align:top"><p>1.2 [0.51, 2.4]</p></td></tr><tr><td style="vertical-align:top"><p>5mg twice daily</p></td><td style="vertical-align:top"><p>171 [91, 321]</p></td><td style="vertical-align:top"><p>103 [41,230]</p></td><td style="vertical-align:top"><p>2.611.4, 4.8]</p></td><td style="vertical-align:top"><p>1.5 [0.61, 3.4]</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Treatment of DVT treatment of PE and prevention of recurrent DVT and PE (VTEt)</em></p></td></tr><tr><td style="vertical-align:top"><p>2.5mg twice daily</p></td><td style="vertical-align:top"><p>67 [30, 153]</p></td><td style="vertical-align:top"><p>32 [11, 90]</p></td><td style="vertical-align:top"><p>1.0 [0.46, 2.5]</p></td><td style="vertical-align:top"><p>0.49 [0.17, 1.4]</p></td></tr><tr><td style="vertical-align:top"><p>5mg twice daily</p></td><td style="vertical-align:top"><p>132 [59, 302]</p></td><td style="vertical-align:top"><p>63 [22, 177]</p></td><td style="vertical-align:top"><p>2.1 [0.91, 5.2]</p></td><td style="vertical-align:top"><p>1.0 [0.33, 2.9]</p></td></tr><tr><td style="vertical-align:top"><p>10 mg twice daily</p></td><td style="vertical-align:top"><p>251 [111, 572]</p></td><td style="vertical-align:top"><p>120 [41, 335]</p></td><td style="vertical-align:top"><p>4.2 [1.8, 10.8]</p></td><td style="vertical-align:top"><p>1.9 [0.64, 5.8]</p></td></tr></tbody></table><p>* Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study.</p><p>Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.</p><p><u>Clinical efficacy and safety</u></p><p><u>Prevention of VTE (VTEp): elective hip or knee replacement surgery </u></p><p>The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement. A total of 8,464 patients were randomised in two pivotal, double-blind, multi-national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients). Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight ( 60 kg), 1,495 patients (743 in the apixaban group) with BMI  33 kg!m2, and 415 patients (203 in the apixaban group) with moderate renal i impairment.</p><p>The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement. Subjects received either apixaban 2.5 mg given orally twice daily (po bid) or enoxaparin 40 mg administered subcutaneously once daily (sc od). The first dose of apixaban was given 12 to 24 hours post-surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Both apixaban and enoxaparin were given for 32-38 days in the ADVANCE-3 study and for 10-14 days in the ADVANCE-2 study.</p><p>Based on patient medical history in the studied population of ADVANCE-3 and ADVANCE-2 (8,464 patients), 46% had hypertension, 10% had hyperlipidemia, 9% had diabetes, and 8% had coronary artery disease.</p><p>Apixaban demonstrated a statistically superior reduction in the primary endpoint, a composite of all VTE/all cause death, and in the Major VIE endpoint, a composite of proximal DVT, non-fatal PE, and VTE-related death, compared to enoxaparin in both elective hip or knee replacement surgery (see Table 4).</p><p>&nbsp;</p><p>Table 4: Efficacy Results from Pivotal Phase III Studies</p><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td><p><strong>Study </strong></p></td><td colspan="3"><p><strong>ADVANCE-3 (hip) </strong></p></td><td colspan="3"><p><strong>ADVANCE-2 (knee) </strong></p></td></tr><tr><td><p>Study treatment</p></td><td><p>Apixaban</p></td><td><p>Enoxaparin</p></td><td rowspan="3"><p>p-value</p></td><td><p>Apixaban</p></td><td><p>Enoxaparin</p></td><td rowspan="3"><p>p-value</p></td></tr><tr><td><p>Dose</p></td><td><p>2.5 mg po twice<br />daily</p><p>&nbsp;</p></td><td><p>40 mg so once<br />daily</p><p>&nbsp;</p></td><td><p>2.5 mg po<strong> </strong><br />twice daily</p></td><td><p>40 mg sc<br />once daily</p></td></tr><tr><td><p>Duration of treatment</p></td><td><p>35&plusmn;3d</p></td><td><p>35&plusmn;3d</p></td><td><p>12&plusmn;2d</p></td><td><p>12&plusmn;2d</p></td></tr><tr><td colspan="7"><p><strong><em>Total VTE/all-cause death </em></strong></p></td></tr><tr><td><p>Number of<br />events/subjects</p></td><td><p>2711,949</p></td><td><p>74/1,917</p></td><td rowspan="3"><p>&lt;0.0001</p></td><td><p>147/976</p></td><td><p>243/997</p></td><td rowspan="3"><p>&lt;0.0001</p></td></tr><tr><td><p>Event Rate</p></td><td><p>1.39%</p></td><td><p>3.86%</p></td><td><p>15.06%</p></td><td><p>24.37%</p></td></tr><tr><td><p>Relative Risk 95% Cl</p></td><td><p>0.36<br />(0.22, 0.54)</p></td><td>&nbsp;</td><td><p>0.62<br />(0.51, 0.74)</p></td><td>&nbsp;</td></tr><tr><td colspan="7"><p><strong><em>Major VTE </em></strong></p></td></tr><tr><td><p>Number of<br />events/subjects</p></td><td><p>10/2,199<br />&nbsp;</p></td><td><p>25/2,195<br />&nbsp;</p></td><td rowspan="3"><p>0.0107</p></td><td><p>1311,195<br />&nbsp;</p></td><td><p>26/1,199<br />&nbsp;</p></td><td rowspan="3"><p>0.0373</p></td></tr><tr><td><p>Event Rate</p></td><td><p>0.45%</p></td><td><p>1.14%</p></td><td><p>1.09%</p></td><td><p>2.17%</p></td></tr><tr><td><p>Relative Risk 95% Cl</p></td><td><p>0.40<br />(0.15, 0.80)</p></td><td>&nbsp;</td><td><p>0.50<br />(0.26, 0.97)</p></td><td>&nbsp;</td></tr></tbody></table><p>The safety endpoints of major bleeding, the composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see Table 5). All the bleeding criteria included surgical site bleeding.</p><p>Table 5: Bleeding Results from Pivotal Phase III Studies*</p><table border="1" cellspacing="0" cellpadding="0" style="width:659px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban<br />2.5mg po twice daily<br />35&plusmn;3d</p></td><td><p>Enoxaparin<br />40 mg sconce daily<br />35&plusmn;3d</p></td><td><p>Apixaban<br />2.5 mg po twice daily<br />12&plusmn;2d</p></td><td><p>Enoxaparin<br />40 mg sconce daily<br />12&plusmn;2d</p></td></tr><tr><td><p>All treated</p></td><td><p>n = 2,673</p></td><td><p>n = 2,659</p></td><td><p>n = 1,501</p></td><td><p>n = 1,508</p></td></tr><tr><td colspan="5"><p><em>Treatment Period1 </em></p></td></tr><tr><td><p>Major</p></td><td><p>22(0.8%)</p></td><td><p>18 (0.7%)</p></td><td><p>9(0.6%)</p></td><td><p><em>14 </em>(0.9%)</p></td></tr><tr><td><p>Fatal</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Major+ CRNM</p></td><td><p>129 (4.8%)</p></td><td><p>134 (5.0%)</p></td><td><p>53(3.5%)</p></td><td><p>72(4.8%)</p></td></tr><tr><td><p>All</p></td><td><p>313(11.7%)</p></td><td><p>334 (12.6%)</p></td><td><p>104(6.9%)</p></td><td><p>126(8.4%)</p></td></tr><tr><td colspan="5"><p><em>Post-surgery treatment period2 </em></p></td></tr><tr><td><p>Major</p></td><td><p>9(0.3%)</p></td><td><p>11(0.4%)</p></td><td><p>4 (0.3%)</p></td><td><p>9 (0.6%)</p></td></tr><tr><td><p>Fatal</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Major <strong>+ </strong>CRNM</p></td><td><p>96 (3.6%)</p></td><td><p>115(4.3%)</p></td><td><p>41(2.7%)</p></td><td><p>56 (3.7%)</p></td></tr><tr><td><p>All</p></td><td><p>261 (9.8%)</p></td><td><p>293 (11.0%)</p></td><td><p>89(5.9%)</p></td><td><p>103(6.8%)</p></td></tr></tbody></table><p>* All the bleeding criteria included surgical site bleeding</p><p>1 Includes events occurring after first dose of enoxaparin (pre-surgery)</p><p>2 Includes events occurring after first dose of apixaban (post-surgery)</p><p>The overall incidences of adverse reactions of bleeding, anaemia and abnormalities of transaminases (e.g., ALT levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery.</p><p>In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PH.</p><p><u>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).</u></p><p>A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES; apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:</p><p>&bull; Prior stroke or transient ischaemic attack (TIA)</p><p>&bull; Age <strong>&ge;</strong> 75 years</p><p>&bull; Hypertension</p><p>&bull; Diabetes mellitus</p><p>&bull; Symptomatic heart failure (NYHA Class  II)</p><p><strong>ARISTOTLE STUDY</strong></p><p>In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months. The mean age was 69.1 years, the mean CHADS2 score was 2.1 and 18.9% of patients had prior stroke or TIA.</p><p>In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (hemorrhagic or ischaemic) and systemic embolism (see Table 6) compared with warfarin.</p><p>Table 6: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Apixaban</p><p>N=9,120</p><p>n (%/yr.)</p></td><td><p>Warfarin</p><p>N=9,081</p><p>n (%/yr.)</p><p dir="RTL">&nbsp;</p></td><td><p>Hazard Ratio</p><p>(95% Cl)</p></td><td><p>p-value</p></td></tr><tr><td><p>Stroke or systemic embolism</p></td><td><p>212 (1.27)</p></td><td><p>265 (1.60)</p></td><td><p>0.79 (0.66, 0.95)</p></td><td><p>0.0114</p></td></tr><tr><td><p>Stroke</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ischemic or unspecified</p></td><td><p>162 (0.97)</p></td><td><p>175 (1.05)</p></td><td><p>0.92 (0.74, 1.13)</p></td><td>&nbsp;</td></tr><tr><td><p>Hemorrhagic</p></td><td><p>40 (0.24)</p></td><td><p>78 (0.47)</p></td><td><p>0.51 (0.35, 0.75)</p></td><td>&nbsp;</td></tr><tr><td><p>Systemic embolism</p></td><td><p>15(0.09)</p></td><td><p>17(0.10)</p></td><td><p>0.87(0.44, 1.75)</p></td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.</p><p>Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% Cl, 0.38, 1.40).</p><p>Key secondary endpoints of major bleeding and all cause death were tested in a pre-specified hierarchical testing strategy to control the overall type I error in the trial. Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 7). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish.</p><p>Table 7: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p>Apixaban<br />N = 9,088<br />n <em>(%/year) </em></p></td><td><p>Warfarin<br />N = 9,052<br />n <em>(%/year) </em></p></td><td><p>Hazard Ratio<br />(95% Cl)<strong> </strong></p></td><td><p>p-value</p></td></tr><tr><td colspan="5"><p>Bleeding Outcomes</p></td></tr><tr><td><p>Major*</p></td><td><p>327 (2.13)</p></td><td><p>462 (3.09)</p></td><td><p>0.69 (0.60, 0.80)</p></td><td><p>&lt;0.0001</p></td></tr><tr><td><p>Fatal</p></td><td><p>10(0.06)</p></td><td><p>37 (0.24)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Intracranial</p></td><td><p>52 (0.33)</p></td><td><p>122 (0.80)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Major + CRNM</p></td><td><p>613 (4.07)</p></td><td><p>877 (6.01)</p></td><td><p>0.68 (0.61, 0.75)</p></td><td><p>&lt;0.0001</p></td></tr><tr><td><p>All</p></td><td><p>2356 (18.1)</p></td><td><p>3060 (25.8)</p></td><td><p>0.71 (0.68, 0.75)</p></td><td><p>&lt;0.0001</p></td></tr><tr><td colspan="5"><p>Other Endpoint</p></td></tr><tr><td><p>All-cause death</p></td><td><p>603 (3.52)</p></td><td><p>669 (3.94)</p></td><td><p>0.89 (0.80, 1.00)</p></td><td><p>0.0465</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>90(0.53)</p></td><td><p>102 (0.61)</p></td><td><p>0.88 (0.66, 1.17)</p></td><td>&nbsp;</td></tr></tbody></table><p>* Major bleeding defined per International Society on Thrombosis and Hemostasis (ISTH) criteria.</p><p>The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.</p><p>The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.</p><p>The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.</p><p>The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.</p><p><strong>AVERROES STUDY</strong></p><p>In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243(2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA.</p><p>Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = I and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%). and difficulty expected difficulty in contacting patient in case of urgent dose change (11.7%).</p><p>AVER ROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile.</p><p>The o1erall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.</p><p>In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (hemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 8) compared to ASA.</p><p>Table 8: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p>Apixaban<br />N = 2,807<br />n (%/year)</p></td><td><p>ASA<br />N = 2,791<br />n <em>(%/year) </em></p></td><td><p>Hazard Ratio<br />(95% Cl)</p></td><td><p>p-value</p></td></tr><tr><td><p>Stroke or systemic embolism*</p></td><td><p><em>51(1.62) </em></p></td><td><p>113 (3.63)</p></td><td><p>0.45(0.32, 0.62)</p></td><td><p>&lt;0.0001</p></td></tr><tr><td><p>Stroke</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ischemic or unspecified</p></td><td><p>43(1.37)</p></td><td><p><em>97(3.11) </em></p></td><td><p>0.44(0.31, 0.63)</p></td><td>&nbsp;</td></tr><tr><td><p>Hemorrhagic</p></td><td><p>6(0.19)</p></td><td><p>9(0.28)</p></td><td><p>0.67(0.24, 1.88)</p></td><td>&nbsp;</td></tr><tr><td><p>Systemic embolism</p></td><td><p>2 (0.06)</p></td><td><p>13 (0.41)</p></td><td><p>0.15 (0.03, 0.68)</p></td><td>&nbsp;</td></tr><tr><td><p>Stroke, systemic embolism, MI, or vascular death*t</p></td><td><p>132 (4.21)</p></td><td><p>197 (6.35)</p></td><td><p>0.66 (0.53, 0.83)</p></td><td><p>0.003</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>24 (0.76)</p></td><td><p>28 (0.89)</p></td><td><p>0.86 (0.50, 1.48)</p></td><td>&nbsp;</td></tr><tr><td><p>Vascular Death</p></td><td><p>84(2.65)</p></td><td><p>96 (3.03)</p></td><td><p>0.87 (0.65, 1.17)</p></td><td>&nbsp;</td></tr><tr><td><p>All-cause death</p></td><td><p>111 (3.51)</p></td><td><p>140 (4.42)</p></td><td><p>0.79 (0.62, 1.02)</p></td><td><p>0.068</p></td></tr></tbody></table><p>* Assessed by sequential testing strategy designed to control the overall type I error in the trial.</p><p>t Secondary endpoint.</p><p>There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 9).</p><p>Table 9: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p><strong>Apixaban<br />N </strong>= <strong>2,798<br />n(%/year) </strong></p></td><td><p><strong>ASA<br />N </strong>= <strong>2,780<br />n (%/year) </strong></p></td><td><p><strong>Hazard Ratio (95%Cl) </strong></p></td><td><p><strong>p-value </strong></p></td></tr><tr><td><p>Major*</p></td><td><p>45 (1.41)</p></td><td><p>29 (0.92)</p></td><td><p>1.54 (0.96, 2.45)</p></td><td><p>0.0716</p></td></tr><tr><td><p>Fatal</p></td><td><p>5(0.16)</p></td><td><p>5(0.16)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Intracranial, n</p></td><td><p>11(0.34)</p></td><td><p>11(0.35)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Major + CRNM<sup>t</sup></p></td><td><p>140(4.46)</p></td><td><p>101 (3.24)</p></td><td><p>1.38 (1.07, 1.78)</p></td><td><p>0.0144</p></td></tr><tr><td><p>All</p></td><td><p>325 (10.85)</p></td><td><p>250 (8.32)</p></td><td><p>1.30 (1.10, 1.53)</p></td><td><p>0.0017</p></td></tr></tbody></table><p>*Major bleeding defined per International Society on Thrombosis ad Hemostasis (ISTH) criteria.</p><p><sup>t</sup> Clinically Relevant Non-Major</p><p><u>Patient&#39;s undergoing cardio version</u></p><p>EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant na&iuml;ve or pretreated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5mg dose).</p><p>There were no strokes (0%) in the apixaban group (n= 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported.</p><p>Major bleeding and CRNM bleeding events occurred in 3(0.41%) and 11(1.50%) patients, respectively, in the apixaban group, compared to 6(0.83%) and 13(1.80%) patients in the heparin and/or VKA group.</p><p>This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.</p><p><u>Treatment of DVT treatment of PE and prevention of recurrent DVT and PE (VTE).</u></p><p>The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.</p><p><strong>AMPLIFY STUDY</strong></p><p>In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.</p><p>The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events.</p><p>For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9. Apixaban showed a reduction in recurrent symptomatic VTE or VTE- related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% Cl,</p><p>0.39, 1.61).</p><p>In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 10).</p><p>Table 10: Efficacy Results in the AMPLIFY Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p>Apixaban<br />N=2,609<br />n(%)</p></td><td><p>Enoxaparin/Warfarin<br />N=2,635<br />n(%)</p></td><td><p>Relative Risk<br />(95% CI)</p></td></tr><tr><td><p>VTE 0rVTE-related death</p></td><td><p>59(2.3)</p></td><td><p>71(2.7)</p></td><td><p>0.84 (0.60, 1.18)*</p></td></tr><tr><td><p>DVT</p></td><td><p>20(0.7)</p></td><td><p>33(1.2)</p></td><td>&nbsp;</td></tr><tr><td><p>PE</p></td><td><p>27(1.0)</p></td><td><p>23(0.9)</p></td><td>&nbsp;</td></tr><tr><td><p>VTE-related death</p></td><td><p>12(0.4)</p></td><td><p>15 (0.6)</p></td><td>&nbsp;</td></tr><tr><td><p>VTE or all-cause death</p></td><td><p>84(3.2)</p></td><td><p>104 (4.0)</p></td><td><p>0.82 (0.61, 1.08)</p></td></tr><tr><td><p>VTE or CV-related death</p></td><td><p>61(2.3)</p></td><td><p>77(2.9)</p></td><td><p>0.80 (0.57, 1.11)</p></td></tr><tr><td><p>VTE, VTE-related death, or major bleeding</p></td><td><p>73(2.8)</p></td><td><p>118 (4.5)</p></td><td><p>0.62 (0.47, 0.83)</p></td></tr></tbody></table><p>* Noninferior compared to enoxaparin/warfarin (p-value &lt;0.0001)</p><p>Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% Cl (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.</p><p>The primary safety endpoint was major bleeding. In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value &lt;0.0001] (see Table 11).</p><p>Table 11: Bleeding Results in the AMPLIFY Study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Apixaban</p><p>N=2,676</p><p><strong>n(%)</strong></p></td><td style="vertical-align:top"><p>Enoxaparin/ Warfarin</p><p>N=2,689</p><p><strong>n(%)</strong></p></td><td style="vertical-align:top"><p>Relative Risk</p><p>(95% Cl)</p></td></tr><tr><td><p>Major</p></td><td><p>15(0.6)</p></td><td><p>49(1.8)</p></td><td><p>0.31 (0.17,0.55)</p></td></tr><tr><td><p>Major+ CRNM</p></td><td><p>115 (4.3)</p></td><td><p>261 (9.7)</p></td><td><p>0.44 (0.36, 0.55)</p></td></tr><tr><td><p>Minor</p></td><td><p>313 (11.7)</p></td><td><p>505 (18.8)</p></td><td><p>0.62(0.54, 0.70)</p></td></tr><tr><td><p>All</p></td><td><p>402 (15.0)</p></td><td><p>676 (25.1)</p></td><td><p>0.59 (0.53, 0.66)</p></td></tr></tbody></table><p>The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group. Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban-treated patients and 17(0.6%) enoxaparin/warfarin-treated patients.</p><p><strong>AMPLIFY-EXT STUDY</strong></p><p>In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment. Of these, 836 patients (33.7%) participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.</p><p>The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.</p><p>In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 12).</p><p>Table 12: Efficacy Results in the AMPLIFY-EXT Study</p><table border="1" cellspacing="0" cellpadding="0" style="width:656px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban</p></td><td><p>Apixaban</p></td><td><p>Placebo</p></td><td colspan="2"><p>Relative Risk (95% Cl)</p></td></tr><tr><td>&nbsp;</td><td><p>2.5 mg (N=840)</p></td><td><p>5.0 mg<br />(N=813)</p></td><td><p>(N=829)</p></td><td><p>Apix 2.5 mg vs.<br />Placebo<strong> </strong></p></td><td><p>Apix 5.0 mg vs.<br />Placebo<strong> </strong></p></td></tr><tr><td colspan="6"><p dir="RTL">n (%)</p></td></tr><tr><td><p>Recurrent VTE or&nbsp; all-cause death</p></td><td><p>19(2.3)</p></td><td><p>14(1.7)</p></td><td><p>77(9.3)</p></td><td><p>0.24<br />(0.15, 0.40)**</p></td><td><p>0.19<br />(0.11, 0.33)**</p></td></tr><tr><td><p>DVT*</p></td><td><p>6(0.7)</p></td><td><p>7(0.9)</p></td><td><p>53(6.4)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>PE*</p></td><td><p>7 (0.8)</p></td><td><p>4(0.5)</p></td><td><p><em>13(1.6) </em></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>all-cause death</p></td><td><p>6(0.7)</p></td><td><p>3(0.4)</p></td><td><p>11(1.3)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Recurrent VTE&nbsp; or VTE-related death</p></td><td><p>14(1.7)</p></td><td><p>14(1.7)</p></td><td><p>73(8.8)</p></td><td><p>0.19<br />(0.11, 0.33)</p></td><td><p>0.20<br />(0.11, 0.34)</p></td></tr><tr><td><p>Recurrent VTE or<br />CV- related death</p></td><td><p>14(1.7)</p></td><td><p>14(1.7)</p></td><td><p>76(9.2)</p></td><td><p>0.18<br />(0.10, 0.32)</p></td><td><p>0.19<br />(0.11, 0.33)</p></td></tr><tr><td><p>Nonfatal DVT<sup>t </sup></p></td><td><p>6(0.7)</p></td><td><p>8(1.0)</p></td><td><p>53(6.4)</p></td><td><p><em>0.11 </em><br />(0.05, 0.26)</p></td><td><p>0.15<br />(0.07, 0.32)</p></td></tr><tr><td><p>Nonfatal&nbsp; PE<sup>t</sup></p></td><td><p>8(1.0)</p></td><td><p>4(0.5)</p></td><td><p>15(1.8)</p></td><td><p>0.51<br />(0.22, 1.21)</p></td><td><p>0.27<br />(0.09, 0.80)</p></td></tr><tr><td><p>VTE-related death</p></td><td><p>2 (0.2)</p></td><td><p>3 (0.4)</p></td><td><p>7 (0.8)</p></td><td><p>0.28<br />(0.06, 1.37)</p></td><td><p>0.45<br />(0.12, 1.71)</p></td></tr></tbody></table><p>**p-value &lt; 0.0001</p><p>* For patients with more than one event contributing to the composite endpoint, only the first event was reported (e.g, if a subject experienced both a DVT and then a PE, only the DVT was reported)</p><p><sup>t </sup>Individual subjects could experience more than one event and be represented in both classifications.</p><p>Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.</p><p>The primary safety endpoint was major bleeding during the treatment period. In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 13).</p><p>Table 13: Bleeding Results in the AMPLIFY-EXT Study</p><table border="1" cellspacing="0" cellpadding="0" style="width:680px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban</p></td><td><p>Apixaban</p></td><td><p>Placebo</p></td><td colspan="2"><p>Relative Risk (95% Cl)</p></td></tr><tr><td>&nbsp;</td><td><p>2.5 mg<br />(N=840)</p></td><td><p>5.0 mg<br />(N=811)</p></td><td><p>(N=826)</p></td><td><p>Apix 2.5 mg vs. Placebo</p></td><td><p>Apix 5.0 mg vs. Placebo</p></td></tr><tr><td colspan="6"><p>n(%)</p></td></tr><tr><td><p><strong>Major</strong></p></td><td><p>2(0.2)</p></td><td><p>1(0.1)</p></td><td><p>4(0.5)</p></td><td><p>0.49<br />(0.09, 2.64)</p></td><td><p>0.25<br />(0.03, 2.24)</p></td></tr><tr><td><p><strong>Major + CRNM</strong></p></td><td><p>27 (3.2)</p></td><td><p>35 (4.3)</p></td><td><p>22 (2.7)</p></td><td><p>1.20<br />(0.69, 2.10)</p></td><td><p>1.62<br />(0.96, 2.73)</p></td></tr><tr><td><p><strong>Minor</strong></p></td><td><p>75(8.9)</p></td><td><p>98(12.1)</p></td><td><p>58(7.0)</p></td><td><p>1.26<br />(0.91, 1.75)</p></td><td><p>1.70<br />(1.25, 2.31)</p></td></tr><tr><td><p><strong>All</strong></p></td><td><p>94(11.2)</p></td><td><p>121 <em>(14.9)</em></p></td><td><p>74(9.0)</p></td><td><p>1.24<br />(0.93,1.65)</p></td><td><p>1.65<br />(1.26, 2.16)</p></td></tr></tbody></table><p>Adjudicated 15TH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban-treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1(0.1%) placebo-treated patient.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with apixaban in one or more subsets of the pediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on pediatric use).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose. Apixaban can be taken with or without food.</p><p>Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses  25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively.</p><p>Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant.</p><p>Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.</p><p>Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses.</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 liters.</p><p><u>Biotransformation and elimination</u></p><p>Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.</p><p>Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours.</p><p>0-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation. Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYPIA2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).</p><p>Renal impairment</p><p>There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.</p><p>In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after hemodialysis, compared to that seen in subjects with normal renal function. Hemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 ml/min. Therefore, hemodialysis is unlikely to be an effective means of managing apixaban overdose.</p><p><u>Hepatic impairment</u></p><p>In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 8) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.</p><p><u>Elderly</u></p><p>Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 32% higher and no difference in Cmax.</p><p><u>Gender</u></p><p>Exposure to apixaban was approximately 18% higher in females than in males.</p><p><u>Ethnic origin and race</u></p><p>The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results.</p><p><u>Body weight </u></p><p>Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight&gt; 120 kg was associated with approximately 30% lower exposure and body weight &lt; 50 kg was associated with approximately 30% higher exposure.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 &mdash;50 mg). The relationship between apixaban plasma concentration and anti-Factor Xa activity was best described by a linear model. The PKIPD relationship observed in patients was consistent with that established in healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development and juvenile toxicity.</p><p>The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Lactose</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystalline cellulose</p></td></tr><tr><td style="vertical-align:top"><p>Crosscarmellose Sodium</p></td></tr><tr><td style="vertical-align:top"><p>Sodium Lauryl Sulphate</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>Opadry White OY-L (28900)</p></td></tr><tr><td style="vertical-align:top"><p>Yellow Iron Oxide</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Paquix<sup>&reg;</sup> 2.5mg F.C. Tablets </strong>are packed in Aluminum foil, PVC/PVDC, blisters, with a multi folded leaflet packed in registration box.</p><p><strong>Pack size: Paquix<sup>&reg;</sup> 2.5mg F.C. Tablets </strong>are packed of 60 F.C. Tablets (10 F.C. Tablets / Blister, 6 Blisters/ Pack) and 30 F.C. Tablets (10 F.C. Tablets / Blister, 3 Blisters/ Pack) in a carton box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma-Saudi  
Almuraba Area
Prince Abdulaziz bin Musaid bin Jalawi Street
Mansour Alrusais Building - F1
Riyadh-KSA
Tel: 00966114010606
Fax: 00966114010606
E-mail: Albaraa.bahhari@mspharma.com  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>